Page last updated: 2024-08-05 11:01:32
polyunsaturated fatty acid
Any fatty acid containing more than one double bond. Acids in this group are reported to have cardioprotective effects; and levels are lowered in chronic fatigue syndrome.
ChEBI ID: 26208
Members (7)
| Member | Definition | Role |
|---|---|---|
| 12-hydroxy-5,8,14-eicosatrienoic acid | 12R-HETrE | |
| 5,8,11-eicosatriynoic acid | A C20 polyunsaturated fatty acid having three triple bonds in the 5-, 8- and 11-positions. | 5,8,11-icosatriynoic acid |
| bay u9773 | A dicarboxylic acid that is that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 4S and a (4-carboxyphenyl)sulfanediyl group at 5R. It is a dual cysteinyl leukotriene receptor antagonist that acts at the CysLT1 and CysLT2 receptors (IC50 = 0.44 and 0.30 muM, respectively). | BAYu9773 |
| decaprenoic acid | A polyunsaturated fatty acid that is octa-2,6-dienoic acid bearing two methyl substituents at positions 3 and 7 (the 2E-isomer). | geranic acid |
| leukotriene a4 | A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid. | leukotriene A4 |
| leukotriene b3 | LTB3 | |
| sq-23377 | A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes. | ionomycin |
Research
Studies (4,750)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 701 (14.76) | 18.7374 |
| 1990's | 2,193 (46.17) | 18.2507 |
| 2000's | 1,235 (26.00) | 29.6817 |
| 2010's | 537 (11.31) | 24.3611 |
| 2020's | 84 (1.77) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 13 (0.27%) | 5.53% |
| Reviews | 73 (1.50%) | 6.00% |
| Case Studies | 11 (0.23%) | 4.05% |
| Observational | 3 (0.06%) | 0.25% |
| Other | 4,751 (97.94%) | 84.16% |